|
 New River's Carrierwave™
triiodothyronine (T3) hormone is being developed as a replacement
or supplemental therapy in patients with primary hypothyroidism
and other indications. The leading thyroid hormone replacement
therapies (HRTs) are based on tetraiodothyronine (T4), and
require deiodination within the patient to convert to the
more active hormone (T3). Patients demonstrate significant
variability in their ability to convert the T4 hormone in
the HRT into T3. This variability can arise as a function
of age, stress or a variety of medical conditions. Commercially
approved drugs based on T3, however, engender certain safety
risks, most notably cardiovascular in nature. The company
hopes that by reducing the variability of the more active
hormone's availability, while reducing the safety risk associated
with other T3 based therapies, NRP409 will mark the first
significant improvement in thyroid HRT-a pharmaceutical segment
that sees roughly 3 billion doses per year in the US-in approximately
half a century.
The company expects to file an IND for NRP409 in the second
quarter of 2006.
|
